PYXS (29) KROS (66) SLGL (54) BBOT (37) ⌘ Pro Terminal →

SIGA Technologies Inc. (SIGA) — RQD Stock Rating Cockpit

$3.04 -4.40% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.02

SIGA Technologies Inc. (SIGA) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (69% profit margin, 43% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY • 68.7% hit rate) →

ROARABLE B • BUY Cap $228.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SIGA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SIGA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, SIGA Technologies Inc. (NASDAQ: SIGA) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $3.04 (-4.40% 1D, market cap $228.5M). Pillar breakdown: Fundamental Cash Engine 20/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, SIGA ranks #73 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SIGA compare to PYXS and KROS in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SIGA carries a Roarable B (72/100 RQD), trailing P/E of 9.8x, gross margin of 68.6%, and ROIC of 42.7%. By comparison, PYXS (Pyxis Oncology Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $226.0M) and KROS (Keros Therapeutics Inc.) posts a C+ grade (66/100 RQD, P/E N/A, ROIC 85.0%, cap $225.2M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while KROS leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SIGA?

▼

Per SIGA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001010086), SIGA Technologies Inc. generated $94.6M in revenue (-31.8% YoY), $23.3M in net income, and $43.5M in free cash flow against $219.5M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (69% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.02 (-0.55%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 20/20 (A+) • 46% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY • 68.7% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+6.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SIGA)Realized 20D OHLCV Swing Band: ±8.8%

Deterministic 5-Pillar Attribution (72/100 Composite)

🔍 WHY SIGA SCORES 72/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+20/20 pts (28% of score)

SEC XBRL FY 2025 (10-K): 46% FCF Margin ($43.5M FCF) & 68.6% Gross Margin

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (24% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade A-$3.16-0.6% Next Q

Q2 (-2Q)

Grade B+$3.14+0.6% Next Q

Q3 (-1Q)

Grade B+$3.16-3.8% Next Q

Current

Grade B$3.04+7% Hist 90D α

Trajectory: A- (80) → B (72)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the SIGA Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 72/100 (B) score, SIGA faces multiple-compression risk if 9.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 66.1% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($3.18) or 200D SMA ($4.36) invalidates the momentum regime and cuts Target Base ($3.23) toward Bear Floor ($2.49).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SIGA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SIGA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 72%NO 28%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

36.730 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

8.22>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

6 / 99-Pt Accounting

52-WEEK LASER RANGE4% OF RANGE

L: $3$3.04H: $8

1. Money & Cash Health● HEALTHY

Are profits real cash in the bank?

Real cash coming in backs up reported profits (69% profit margin and healthy balance-sheet cushion).

Factor Grade: A+RQD 20 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: D+RQD 23 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: BRQD 29 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on SIGA

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (98)

42.7% ROIC with 68.6% gross margin and 19.03% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (80)

Altman-Z 8.22 and Piotroski 6/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (60)

23/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like SIGA

✓Strong cash generator (69% profit margin)—profits are backed by real money, not accounting tricks.
✓Company leadership has skin in the game with net positive insider conviction.
✓Clean SEC annual filing review with no major hidden accounting time-bombs.

Bear Case: What Could Go Wrong

!Broader market pullbacks can still drag down strong stocks in the short run.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (SIGA Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SIGA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -34.34%▼ SUPPORT BREAKDOWN

2026-11-02O $3.03H $3.04L $2.91C $3.04VOL 288.9K

RES: $3.43SUP: $3.10SMA50: $3.18SMA200: $4.36

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SIGA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SIGA Butterfly Map → + Track SIGA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-1.6%/yr Implied 5Y Growth

vs. -31.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SIGA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SIGA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SIGA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SIGA)

Health Care Rank #73 of 1016 ⚔️ PYXS vs SIGA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SIGA vs. PYXS, KROS, SLGL, BBOT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, SIGA Technologies Inc. (SIGA) ranks #73 by composite RQD confidence (72/100, grade B) and #558 by equity capitalization ($228.5M). Within this direct 5-issuer industry benchmark cohort, SIGA leads on earnings valuation at 9.8x trailing P/E, while KROS leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. SIGA currently leads its immediate peer cohort in composite quantitative strength at 72/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SIGA ACTIVE SIGA Technologies Inc.	B	72/100	9.8x	68.6%	42.7%	-4.40%	$228.5M	Benchmark Subject
PYXS Pyxis Oncology Inc.	E	29/100	—	82.8%	-35.0%	-4.23%	$226.0M	/pyxs-vs-siga →
KROS Keros Therapeutics Inc.	C+	66/100	—	—	85.0%	-2.82%	$225.2M	/kros-vs-siga →
SLGL Sol-Gel Technologies Ltd.	D+	54/100	—	—	-35.0%	-0.45%	$224.8M	/slgl-vs-siga →
BBOT BridgeBio Oncology Therapeutics Inc.	D-	37/100	—	—	-35.0%	-2.96%	$216.5M	/bbot-vs-siga →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001010086

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SIGA Technologies Inc. (SIGA) reported GAAP revenue of $94.6M (-31.8% vs. FY2024 revenue of $138.7M , and -32.4% cumulative change since FY2023) , GAAP net income of $23.3M, operating cash flow of $43.5M, and free cash flow of $43.5M (-10.8% YoY). On the balance sheet, SIGA closed FY2025 with $219.5M in total assets against $0 in total debt (Altman Z-Score: 8.22, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$94.6M	$23.3M	$43.5M	$43.5M	$219.5M	—
FY2024 (FY)	2024-12-31	$138.7M	$59.2M	$48.8M	$48.8M	$244.3M	—
FY2023 (FY)	2023-12-31	$139.9M	$68.1M	$94.8M	$94.8M	—	—

3. SIGA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SIGA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SIGA compare to PYXS and KROS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SIGA?

Where is SIGA trading relative to its 50-day, 200-day, and 52-week technical levels?

SIGA last traded at $3.04 (-4.40% on volume of 504,686 shares), positioning the stock -4.40% below its 50-day simple moving average ($3.18) and -30.28% below its 200-day simple moving average ($4.36). Across its 52-week range of $2.83 to $8.46, SIGA sits at the 3.7% percentile with a 14-day RSI of 36.7 (NEUTRAL RANGE) and an implied next-earnings move of ±8.8% ($2.77 to $3.31).

SIGA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell SIGA stock right now?

SIGA Technologies Inc. (SIGA) currently earns a Roarable Rating of B (Buy — BUY) with 72/100 RQD Confidence. High-quality cash engine (69% profit margin, 43% return on capital) with steady institutional support.

What is SIGA's 12-month price target and RQD AI Jury consensus?

SIGA's 12-month base price target is $3.23 (range $2.49 to $8.88), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: SIGA RQD Cockpit SIGA 12M Forecast SIGA Earnings & Move SIGA Dividends & DRIP SIGA Insiders & 13F SIGA Whale Options SIGA Profit Sankey SIGA News & Why

ROARABLE RATING BRIEF • RQD 72/100 (B) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SIGA — SIGA Technologies Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:40:28Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, SIGA scores 72 out of 100, graded B and labeled "Roarable Buy — Good Risk/Reward." The five pillars are:

Fundamental Cash Engine: 20 / 20. Per the RQD rating, this pillar reflects ROIC of 42.7% and an FCF yield of 19.03%. This is the strongest pillar and the main upside driver in the source data: the business converts capital and revenue into cash at a high rate relative to its market value.
Whale 13F Flow: 6 / 20. Per the RQD rating, this pillar covers institutional accumulation and options positioning. It is the weakest pillar. The source data contains no holder detail (see Analyst View section), so the low score is not explained further.
Insider Conviction: 17 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The score is solid, though the underlying trade records are not included in the source data.
Macro Regime Fit: 13 / 20. Per the RQD rating, beta is 1.0 with a sector sensitivity component. This is a middling score that indicates the stock's moves track the broad market roughly one-for-one, offering neither a defensive cushion nor extra leverage to market direction.
Forensic Balance Sheet: 16 / 20. Per the RQD rating, Altman Z is 8.22, Piotroski F is 6/9, and Debt/Equity is 0.5. These figures point to a financially sound balance sheet by the rating's measures.

For a prospective investor evaluating the stock today, the rating points to a cash-generative business trading at a low multiple (P/E TTM 9.8, EV/EBITDA 4.8 per market data). The main valuation tradeoff is that revenue fell from $138.7M in FY 2024 to $94.6M in FY 2025 (per the SEC financials), so the high cash-return metrics rest on a shrinking top line. The weak whale-flow pillar means institutional conviction signals are not a current support. This is an analytical summary, not personalized advice.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
3.18	$228.5M	9.8	9.1	4.8	0.32	0%	1.0	$2.91 - $3.61	42.7%

Business

SIGA Technologies Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the profile. The source data does not describe its products, customers, or revenue model beyond the news items noted below. Per the recent news wire, the company has a contract with Public Services and Procurement Canada to supply Oral TPOXX to the Canadian Department of National Defence. Customer and product detail beyond that is not available in source data.

Open Questions

What are SIGA's revenue sources and product lines, and how concentrated is revenue among government customers such as the Canadian Department of National Defence?
Why did revenue fall from $138.7M (FY 2024) to $94.6M (FY 2025) and operating income fall from $83.6M (FY 2023) to $23.7M (FY 2025), and is the decline expected to continue?
What are total debt, EPS by period, and FY 2023 cash, which are missing from the financials?
Does the reported Q2 revenue figure of USD 41.00 million reconcile with the annual financials, and what period does it cover?
What explains the weak whale-flow pillar score (6/20) given no holder data is available, and what insider trades underlie the insider conviction score?

SIGA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for SIGA Technologies Inc. (SIGA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SIGA Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 6h ago

SIGA Technologies, Inc. (SIGA) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering SIGA Technologies Inc. (SIGA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 9h ago

Siga Technologies (NASDAQ:SIGA) Shares Cross Above 50-Day Moving Average - Here's What Happened

MarketBeat report covering SIGA Technologies Inc. (SIGA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST www.marketscreener.com • 12h ago

SIGA Technologies, Inc. Secures Contract from Public Services and Procurement Canada to Supply Oral Tpoxx to Canadian Department of National Defence

www.marketscreener.com report covering SIGA Technologies Inc. (SIGA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 15h ago

SIGA Technologies Slips to $3.12 as Shares Test Lower End of Recent Range - Short Setup Alerts

https://www.dars.gov.et/ report covering SIGA Technologies Inc. (SIGA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST ad-hoc-news.de • 18h ago

SIGA Technologies stock gets new Canadian TPOXX contract

ad-hoc-news.de report covering SIGA Technologies Inc. (SIGA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 21h ago

SIGA stock: Q2 revenue reached USD 41.00 million. SIGA stock is valued at USD 224.20 million

ad-hoc-news.de report covering SIGA Technologies Inc. (SIGA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

SIGA targets 2027 FDA filing: what it means for SIGA stock

ad-hoc-news.de report covering SIGA Technologies Inc. (SIGA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TipRanks • 1d ago

Siga Technologies awarded $15M oral Tpoxx contract from PSPC

TipRanks report covering SIGA Technologies Inc. (SIGA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SIGA Bull vs. Bear Conversation Board — What's Your Call at $3.04?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SIGA 🐻 33% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $3.75 (+17.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is SIGA (B • RQD 72/100) a Buy at $3.18?

Welcome to the SIGA (SIGA Technologies Inc.) Roar Pit. Current RQD Composite is 72/100 (Roarable Buy — Good Risk/Reward) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (42.7% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.67 (-16.0%)

Spot @ $3.18

Pump the brakes on SIGA — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SIGA, but look at what you are paying: 9.8x trailing P/E with 68.6% gross margins. Unless SIGA Technologies Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $3.78 (+18.9%)

Spot @ $3.18

SIGA cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SIGA, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.18 (52-wk range $2.91 - $3.61), any beat on forward guidance forces shorts and underweight funds to chase.